ALTO NEUROSCIENCE INC (ANRO)

US02157Q1094 - Common Stock

14.34  +0.05 (+0.35%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ANRO. ANRO was compared to 196 industry peers in the Pharmaceuticals industry. While ANRO seems to be doing ok healthwise, there are quite some concerns on its profitability. ANRO has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ANRO has reported negative net income.
In the past year ANRO has reported a negative cash flow from operations.

1.2 Ratios

Looking at the Return On Assets, with a value of -41.91%, ANRO is in line with its industry, outperforming 42.27% of the companies in the same industry.
ANRO has a Return On Equity (-52.01%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -41.91%
ROE -52.01%
ROIC N/A
ROA(3y)-42.77%
ROA(5y)N/A
ROE(3y)-56.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ANRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANRO has about the same amount of shares outstanding.
Compared to 1 year ago, ANRO has an improved debt to assets ratio.

2.2 Solvency

An Altman-Z score of 12.16 indicates that ANRO is not in any danger for bankruptcy at the moment.
ANRO's Altman-Z score of 12.16 is amongst the best of the industry. ANRO outperforms 84.54% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that ANRO is not too dependend on debt financing.
The Debt to Equity ratio of ANRO (0.14) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 12.16
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 15.22 indicates that ANRO has no problem at all paying its short term obligations.
ANRO has a better Current ratio (15.22) than 87.11% of its industry peers.
ANRO has a Quick Ratio of 15.22. This indicates that ANRO is financially healthy and has no problem in meeting its short term obligations.
ANRO has a better Quick ratio (15.22) than 87.11% of its industry peers.
Industry RankSector Rank
Current Ratio 15.22
Quick Ratio 15.22

More info and screens

0

3. Growth

3.1 Past

ANRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.44%.
EPS 1Y (TTM)-31.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ANRO is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.81% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y44.33%
EPS Next 2Y19.11%
EPS Next 3Y6.81%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANRO. In the last year negative earnings were reported.
Also next year ANRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.11%
EPS Next 3Y6.81%

More info and screens

0

5. Dividend

5.1 Amount

ANRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALTO NEUROSCIENCE INC

NYSE:ANRO (10/22/2024, 12:50:41 PM)

14.34

+0.05 (+0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap386.61M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.91%
ROE -52.01%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 15.22
Quick Ratio 15.22
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-31.44%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y44.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y